Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol 0.2% Eye Drops for Retinopathy of Prematurity
NCT02504944Phase 2Completed
- Sponsor
- Meyer Children's Hospital IRCCS
- Start
- Jul 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of propranolol in retinopathy of prematurity (ROP), sponsored by Meyer Children's Hospital IRCCS. Primary endpoints: Incidence rate of progression from stage 1 ROP to zone II stage 2 ROP with plus, Incidence rate of progression from stage 1 ROP to zone II stage 3 ROP with plus and 1 more. Started Jul 2015; status: completed.
02
Drugs
propranolol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT02504944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504944.